Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID,Condition 1a,Condition 1b 1301,"Ribbhammar U, et al., Hum Mol Genet 2003 Sep 1;12(17):2087-96.",joint integrity trait,,RS:0002061,LEW.1AV1/Kini,both,0 days,12,,CMO:0001453,percentage of study population developing experimental arthritis during a period of time,,,,0,%,,,MMO:0000163,in vivo visual assessment,,0.0,,,,,Freund's incomplete adjuvant (200 ul) ,70189,Freund's incomplete adjuvant (200 ul) , 1178,"de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84.",peripheral nervous system integrity trait,peripheral nervous system integrity trait,RS:0002061,LEW.1AV1/Kini,male,200 days to 98 days,41,,CMO:0001522,percentage of study population developing experimental autoimmune neuritis during a period of time,,,,100,%,,,MMO:0000162,ex vivo visual assessment,,0.0,,,,,peripheral nerve myelin (2 mg) and Freund's complete adjuvant (100 ul) ,84522,peripheral nerve myelin (2 mg) ,Freund's complete adjuvant (100 ul) 1178,"de Graaf KL, et al., J Neuroimmunol. 2004 Oct;155(1-2):73-84.",peripheral nervous system integrity trait,peripheral nervous system integrity trait,RS:0002061,LEW.1AV1/Kini,male,200 days to 98 days,6,,CMO:0001522,percentage of study population developing experimental autoimmune neuritis during a period of time,,,,100,%,,,MMO:0000162,ex vivo visual assessment,,0.0,,,,,peripheral myelin protein 2 peptide 58-81 (100 ug) and Freund's complete adjuvant (100 ul) ,84536,peripheral myelin protein 2 peptide 58-81 (100 ug) ,Freund's complete adjuvant (100 ul)